We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biomarkers Discovered for Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 05 Jun 2013
A number of biomarkers have been identified for inflammatory bowel disease, which could help with earlier diagnosis and intervention in those who have not yet shown symptoms.

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine and the main types of IBD are Crohn's disease and ulcerative colitis. More...
These bowel diseases are considered autoimmune diseases in which the patient’s own immune system attacks elements of the digestive system.

Gastroenterologists at the Division of Digestive Diseases at the University of Cincinnati (OH, USA) used the US Department of Defense Serum Repository (DoDSR; Silver Spring, MD, USA), to identify all of the active duty service men and women who developed IBD and then used the repository to go back and look at various biomarkers to see what each person had in common.

In this study, the scientists used the repository to identify 50 cases of Crohn's disease and 50 cases of ulcerative colitis. They analyzed proteins from three samples per case, with two taken before and one after diagnosis and then processed the results using a statistical analysis format. Certain proteins were found in elevated levels in samples from patients who developed IBD.

Bruce Yacyshyn, MD, the lead investigator, said, “The selection of proteins we chose to analyze was based on a prior study conducted at the University of Cincinnati. Although the presence of proteins in those who develop Crohn's disease varies from those present in ulcerative colitis patients, we were able to show that there were elevated levels of certain proteins in patients who developed IBD. Future large validation studies are needed to confirm the presence of biomarkers to guide in diagnosis, prevention, and management of these patients. This could change the way we currently screen for and treat IBD, which could improve prevention strategies, patient outcomes, and their overall quality of life.” The study was presented by staff from the Walter Reed National Military Medical Center (Bethesda, MD, USA) at the Digestive Disease Week 2013, held May 18–21, 2013 in Orlando (FL, USA; ).


Related Links:

University of Cincinnati
US Department of Defense Serum Repository
Walter Reed National Military Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.